Tomoko Hayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6983996/publications.pdf

Version: 2024-02-01

70 papers 4,409 citations

30 h-index 106344 65 g-index

71 all docs

71 docs citations

times ranked

71

6101 citing authors

#	Article	IF	CITATIONS
1	Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology, 2004, 126, 520-528.	1.3	817
2	Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology, 2002, 122, 1428-1441.	1.3	333
3	The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell, 2016, 167, 1525-1539.e17.	28.9	318
4	Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. Journal of Clinical Investigation, 2004, 114, 270-279.	8.2	297
5	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight, 2017, 2, .	5.0	203
6	3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18619-18624.	7.1	161
7	IFN- $\hat{l}\pm\hat{l}^2$ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines. Journal of Immunology, 2002, 168, 4907-4913.	0.8	117
8	Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7479-7484.	7.1	112
9	Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites. Journal of Immunology, 2001, 167, 1584-1591.	0.8	100
10	Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2764-2769.	7.1	100
11	Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3990-3995.	7.1	98
12	Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates. Bioconjugate Chemistry, 2009, 20, 1194-1200.	3.6	95
13	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. Journal of Virology, 2015, 89, 3221-3235.	3.4	92
14	Vaccination with Irradiated Listeria Induces Protective T Cell Immunity. Immunity, 2006, 25, 143-152.	14.3	86
15	Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. Journal of Allergy and Clinical Immunology, 2004, 113, 448-454.	2.9	82
16	Identification of Substituted Pyrimido [5,4- <i>b</i>) jindoles as Selective Toll-Like Receptor 4 Ligands. Journal of Medicinal Chemistry, 2013, 56, 4206-4223.	6.4	76
17	Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine, 2002, 20, 3342-3354.	3.8	75
18	TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant. Journal of Translational Medicine, 2014, 12, 211.	4.4	75

#	Article	IF	CITATIONS
19	Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Cancer Immunology Research, 2019, 7, 1714-1726.	3.4	72
20	Enhancement of Innate Immunity against <i>Mycobacterium avium</i> Infection by Immunostimulatory DNA Is Mediated by Indoleamine 2,3-Dioxygenase. Infection and Immunity, 2001, 69, 6156-6164.	2.2	71
21	Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine, 1997, 15, 1598-1605.	3.8	61
22	TLR9-Based Immunotherapy for Allergic Disease. American Journal of Medicine, 2006, 119, 897.e1-897.e6.	1.5	46
23	Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjugate Chemistry, 2015, 26, 1713-1723.	3.6	38
24	Role of CD40 Ligand in Mycobacterium avium Infection. Infection and Immunity, 1999, 67, 3558-3565.	2.2	38
25	Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzymeâ€Directed Assembly. Advanced Healthcare Materials, 2019, 8, e1901105.	7.6	35
26	Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R123-R132.	1.8	32
27	Importance of Toll-Like Receptor 9 in Host Defense against M1T1 Group A <i>Streptococcus </i> Infections. Journal of Innate Immunity, 2012, 4, 213-218.	3.8	32
28	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Journal of Virology, 2017, 91, .	3.4	32
29	Generation and Application of a Reporter Cell Line for the Quantitative Screen of Extracellular Vesicle Release. Frontiers in Pharmacology, 2021, 12, 668609.	3.5	32
30	Synthesis and Characterization of PEGylated Toll Like Receptor 7 Ligands. Bioconjugate Chemistry, 2011, 22, 445-454.	3.6	30
31	Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes. PLoS ONE, 2015, 10, e0129867.	2.5	27
32	Intravesical Tollâ€ike receptor 7 agonist Râ€837: Optimization of its formulation in an orthotopic mouse model of bladder cancer. International Journal of Urology, 2010, 17, 483-490.	1.0	26
33	Cutting Edge: Nitrogen Bisphosphonate-Induced Inflammation Is Dependent upon Mast Cells and IL-1. Journal of Immunology, 2012, 188, 2977-2980.	0.8	24
34	Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Research, 2011, 21, 66-75.	1.2	22
35	Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11163-11168.	7.1	22
36	Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue. Journal of Mass Spectrometry, 2013, 48, 768-773.	1.6	22

#	Article	IF	CITATIONS
37	Induction and Inhibition of the Th2 Phenotype Spread: Implications for Childhood Asthma. Journal of Immunology, 2005, 174, 5864-5873.	0.8	21
38	In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. Cellular Immunology, 2008, 251, 78-85.	3.0	21
39	Cell-penetrating peptide CGKRK mediates efficient and widespread targeting of bladder mucosa following focal injury. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1925-1932.	3.3	21
40	Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4931-4938.	2.2	20
41	Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System. PLoS ONE, 2012, 7, e45860.	2.5	20
42	Identification of Biologically Active Pyrimido[5,4- <i>b</i>) indoles That Prolong NF-ÎB Activation without Intrinsic Activity. ACS Combinatorial Science, 2017, 19, 533-543.	3.8	19
43	Localized <i>In Vivo</i> Activation of a Photoactivatable Doxorubicin Prodrug in Deep Tumor Tissue. Photochemistry and Photobiology, 2013, 89, 698-708.	2.5	18
44	Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and \hat{l}_{\pm} -Mannose as Adjuvants. Bioconjugate Chemistry, 2019, 30, 2811-2821.	3.6	18
45	Analysis of highâ€throughput screening assays using cluster enrichment. Statistics in Medicine, 2012, 31, 4175-4189.	1.6	17
46	Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6836-E6844.	7.1	17
47	Innate Immune Protection against Infectious Diseases by Pulmonary Administration of a Phospholipid-Conjugated TLR7 Ligand. Journal of Innate Immunity, 2014, 6, 315-324.	3.8	16
48	A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity. Frontiers in Immunology, 2020, 11, 1207.	4.8	16
49	Novel Synthetic Toll-Like Receptor 4/MD2 Ligands Attenuate Sterile Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 330-340.	2.5	15
50	Fluorescent-tilmanocept for tumor margin analysis in the mouse model. Journal of Surgical Research, 2014, 190, 528-534.	1.6	14
51	Recent Advances and Perspectives in Small-molecule TLR Ligands and Their Modulators. ACS Medicinal Chemistry Letters, 2018, 9, 1156-1159.	2.8	14
52	A clinico-epidemiological analysis ofHelicobacter pylori (H. pylori) by Southern blotting with A urease gene probe. Journal of Gastroenterology, 1994, 29, 120-124.	5.1	13
53	Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity. ACS Applied Materials & Dividing the Company of the Conjugation of the	8.0	13
54	CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages. FEMS Immunology and Medical Microbiology, 2005, 45, 303-310.	2.7	12

#	Article	IF	CITATIONS
55	A traditional Japanese medicine mitigates TNBS-induced colitis in rats. Scandinavian Journal of Gastroenterology, 2006, 41, 1183-1189.	1.5	12
56	Release of monocyte chemoattractant protein (MCP)-1 by a human alveolar epithelial cell line in response toMycobacterium avium. FEMS Immunology and Medical Microbiology, 2000, 29, 1-7.	2.7	11
57	Chromosomal heterogeneity of Helicobacter pylori isolates by pulsed-field gel electrophoresis. Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology, 1993, 280, 120-127.	0.5	10
58	Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy. BioMed Research International, 2018, 2018, 1-13.	1.9	10
59	The Role of Plasmacytoid and Myeloid Dendritic Cells in Induction of Asthma in a Mouse Model and the Effect of a TLR9 Agonist on Dendritic Cells. Allergy, Asthma and Immunology Research, 2011, 3, 199.	2.9	9
60	Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects. European Journal of Dermatology, 2013, 23, 618-628.	0.6	9
61	Identification of Compounds That Prolong Type I Interferon Signaling as Potential Vaccine Adjuvants. SLAS Discovery, 2018, 23, 960-973.	2.7	9
62	Identification of a chemotactic, MCP-1-like protein fromMycobacterium avium. FEMS Immunology and Medical Microbiology, 2002, 33, 115-124.	2.7	8
63	Structure–Activity Relationship Studies To Identify Affinity Probes in Bis-aryl Sulfonamides That Prolong Immune Stimuli. Journal of Medicinal Chemistry, 2019, 62, 9521-9540.	6.4	8
64	Mast Cell-Mediated Inhibition of Abdominal Neutrophil Inflammation by a PEGylated TLR7 Ligand. Mediators of Inflammation, 2012, 2012, 1-10.	3.0	7
65	Detection of mitochondrial DNA nucleotide 11778 point mutation of Leber hereditary optic neuropathy from archival stained histopathological preparations. Acta Ophthalmologica, 1998, 76, 14-19.	0.3	6
66	Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	6
67	Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF- \hat{P} B activation. Bioorganic and Medicinal Chemistry, 2021, 43, 116242.	3.0	5
68	Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 400-402.	1.3	4
69	Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126840.	2.2	3
70	A Triple High Throughput Screening for Extracellular Vesicle Inducing Agents With Immunostimulatory Activity. Frontiers in Pharmacology, 2022, 13, 869649.	3.5	2